Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
| Bascom Palmer Eye Institute | OTHER |
| New York Presbyterian Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.
The purpose of this study is to test the effectiveness of a drug, bevacizumab (Avastin), in preventing blood vessels that often occur after a corneal transplantation which are considered at "high-risk" for rejection. In many cases these blood vessels lead to the graft rejection and eventual failure of the corneal transplant. It is hoped that this treatment will increase the chances of corneal graft survival.
The medication used in this study is called bevacizumab or Avastin (Genentech, Inc). It works by inhibiting the action of a molecule called vascular endothelial growth factor (VEGF). VEGF is a substance molecule that binds to certain cells to stimulate new blood vessel formation. When VEGF is bound to the drug, it cannot stimulate the formation and growth of new blood vessels. Growth of blood vessels into the cornea is a complication which can worsen the prognosis of your corneal transplant and put the transplant at a higher risk for rejection.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Avastin® (bevacizumab) | Active Comparator | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. |
|
| 0.9% NaCl & Refresh Liquigel | Placebo Comparator | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avastin® (bevacizumab) | Drug | One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Endothelial Rejection Rate | Endothelial rejection rates in patients in the treatment group and the control group were calculated using the Kaplan-Meier survival curve. The Kaplan-Meier/product limit estimator is a non-parametric statistical test used to show the probability of an event occurring at a given time interval. The Kaplan-Meier estimator is used to show what the probability of corneal transplant rejection (and therefore transplant survival) after administration of the active treatment or control. | 12 Months |
| Number of Participants Experiencing Ocular Adverse Events | Incidence and severity of ocular adverse events during the study (based on ophthalmic examination and subject self-reporting). | 12 months |
| Incidence of Systemic Adverse Events | Incidence and severity of systemic adverse events during the study (based on physical examination, subject self-reporting, and changes in vital sign). | 12 Months |
Not provided
Not provided
Inclusion Criteria:
Age > 18 years
Participant willing and able to provide written informed consent
Willing and able to comply with study assessments for the full duration of the study
High-risk characteristics for penetrating keratoplasty:
In generally good stable overall health
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Reza Dana, MD, MPH, MSc | Massachusetts Eye and Ear Infirmary | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | United States | ||
| Massachusetts Eye and Ear Infirmary |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Avastin® (Bevacizumab) | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. Avastin® (bevacizumab): One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 8, 2015 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 0.9% NaCl & Refresh Liquigel | Drug | One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks. |
|
|
| Boston |
| Massachusetts |
| 02114 |
| United States |
| New York Presbyterian Hospital | New York | New York | 10065 | United States |
| FG001 | 0.9% NaCl & Refresh Liquigel | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. 0.9% NaCl & Refresh Liquigel: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Avastin® (Bevacizumab) | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. Avastin® (bevacizumab): One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks. |
| BG001 | 0.9% NaCl & Refresh Liquigel | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. 0.9% NaCl & Refresh Liquigel: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Endothelial Rejection Rate | Endothelial rejection rates in patients in the treatment group and the control group were calculated using the Kaplan-Meier survival curve. The Kaplan-Meier/product limit estimator is a non-parametric statistical test used to show the probability of an event occurring at a given time interval. The Kaplan-Meier estimator is used to show what the probability of corneal transplant rejection (and therefore transplant survival) after administration of the active treatment or control. | Posted | Count of Participants | Participants | 12 Months |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Experiencing Ocular Adverse Events | Incidence and severity of ocular adverse events during the study (based on ophthalmic examination and subject self-reporting). | Posted | Count of Participants | Participants | 12 months |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Incidence of Systemic Adverse Events | Incidence and severity of systemic adverse events during the study (based on physical examination, subject self-reporting, and changes in vital sign). | Posted | Count of Participants | Participants | 12 Months |
|
12 months
All the subjects once enrolled into study were followed for the duration of the study (12 months) and examined for systematic and ocular adverse events at every study visit. Any adverse events that discovered by the study staff during the study visits were added to the Adverse Events Log. At every visit study subjects were also asked if any Adverse Events occurred in between study visits.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Avastin® (Bevacizumab) | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. Avastin® (bevacizumab): One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks. | 0 | 39 | 2 | 39 | 34 | 39 |
| EG001 | 0.9% NaCl & Refresh Liquigel | Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks. The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule. 0.9% NaCl & Refresh Liquigel: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks. | 0 | 36 | 4 | 36 | 35 | 36 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation (subject was hospitalized for 3 days) | Cardiac disorders | Systematic Assessment |
| ||
| Urinary Track Infection (subject hospitalized for 3 days) | Renal and urinary disorders | Systematic Assessment |
| ||
| congestive heart failure (subject hospitalized) | Cardiac disorders | Systematic Assessment |
| ||
| Pulmonary embolism | Infections and infestations | Systematic Assessment |
| ||
| a stroke | Nervous system disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| AC cells in study eye | Eye disorders | Systematic Assessment |
| ||
| AC cells (OS) | Eye disorders | Systematic Assessment |
| ||
| Acanthamoeba infection in study eye | Eye disorders | Systematic Assessment |
| ||
| Acute graft edema | Eye disorders | Systematic Assessment |
| ||
| Allergic reaction to Bacitracin | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Allergic reaction to medications prescribed for congestive heart failure | Cardiac disorders | Systematic Assessment |
| ||
| Asthma exacerbation | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Back Pain | General disorders | Systematic Assessment |
| ||
| Blurred vision (OD) | Eye disorders | Systematic Assessment |
| ||
| Blurry vision (OS) | Eye disorders | Systematic Assessment |
| ||
| Blurry vision (OU) | Eye disorders | Systematic Assessment |
| ||
| Blurry vision in study eye | Eye disorders | Systematic Assessment |
| ||
| Blurry vision | Eye disorders | Systematic Assessment |
| ||
| Broken sutures (2 broken sutures) | Eye disorders | Systematic Assessment |
| ||
| Burning in study eye | Eye disorders | Systematic Assessment |
| ||
| Central epithelial defect in study eye | Eye disorders | Systematic Assessment |
| ||
| Central scotoma in OD (non-study eye) | Eye disorders | Systematic Assessment |
| ||
| Cloudy vision in study eye | Eye disorders | Systematic Assessment |
| ||
| Cloudy vision | Eye disorders | Systematic Assessment |
| ||
| Conjunctivitis | Eye disorders | Systematic Assessment |
| ||
| Corneal edema (OS) | Eye disorders | Systematic Assessment |
| ||
| Corneal infiltrate near the suture | Eye disorders | Systematic Assessment |
| ||
| Corneal Transplant | Eye disorders | Systematic Assessment |
| ||
| Corneal ulcer | Eye disorders | Systematic Assessment |
| ||
| Dark spot in central vision upon awakening each morning | Eye disorders | Systematic Assessment |
| ||
| Darkening of vision (OD) | Eye disorders | Systematic Assessment |
| ||
| Decrease in vision | Eye disorders | Systematic Assessment |
| ||
| Decrease in vision following intravitreal injection of Eylea | Eye disorders | Systematic Assessment |
| ||
| Descement's folds (OS) | Eye disorders | Systematic Assessment |
| ||
| Difficulty seeing (OU) | Eye disorders | Systematic Assessment |
| ||
| Difficulty/pain with walking caused by recent arthritis | General disorders | Systematic Assessment |
| ||
| Dimming of vision (OD) | Eye disorders | Systematic Assessment |
| ||
| Diplopia & glare at night when driving (OS) | Eye disorders | Systematic Assessment |
| ||
| Discomfort with tearing and burning | Eye disorders | Systematic Assessment |
| ||
| Double vision (OU) | Eye disorders | Systematic Assessment |
| ||
| Dry eye | Eye disorders | Systematic Assessment |
| ||
| Dry eye from allergies in study eye | Eye disorders | Systematic Assessment |
| ||
| Ear wax in the ear causing pain in the ear and face | Ear and labyrinth disorders | Systematic Assessment |
| ||
| High intraocular pressure | Eye disorders | Systematic Assessment |
| ||
| Low intraocular pressure | Eye disorders | Systematic Assessment |
| ||
| Endothelial (Khodadoust) rejection | Eye disorders | Systematic Assessment |
| ||
| Epithelial defect | Eye disorders | Systematic Assessment |
| ||
| Flashes | Eye disorders | Systematic Assessment |
| ||
| Floaters | Eye disorders | Systematic Assessment |
| ||
| Floaters following a clinical laser procedure | Eye disorders | Systematic Assessment |
| ||
| Floater following intravitreal injection of Eylea | Eye disorders | Systematic Assessment |
| ||
| Foreign body sensation | Eye disorders | Systematic Assessment |
| ||
| Graft rejection | Eye disorders | Systematic Assessment |
| ||
| Green discharge in operative eye | Eye disorders | Systematic Assessment |
| ||
| Headache | General disorders | Systematic Assessment |
| ||
| Headaches due to ocular pain | Eye disorders | Systematic Assessment |
| ||
| Herpes keratitis | General disorders | Systematic Assessment |
| ||
| High blood pressure | General disorders | Systematic Assessment |
| ||
| Hospitalization for shortness of breath with logs of edema in legs and fluid in lungs | General disorders | Systematic Assessment |
| ||
| Increase in the frequency of stinging when instilling eye drops | Eye disorders | Systematic Assessment |
| ||
| Infection from scleral lenses in non-study eye | Eye disorders | Systematic Assessment |
| ||
| Irregular heartbeat | Cardiac disorders | Systematic Assessment |
| ||
| Itchy eye | Eye disorders | Systematic Assessment |
| ||
| Left periocular trauma with an electrical cord plug. No injury to the eye. No symptoms. Subject feel | Eye disorders | Systematic Assessment |
| ||
| Eye lid pain | Eye disorders | Systematic Assessment |
| ||
| Light sensitivity in study eye | Eye disorders | Systematic Assessment |
| ||
| Mild irritation in the operative eye following a Lucentis injection | Eye disorders | Systematic Assessment |
| ||
| Mild edema in graft | Eye disorders | Systematic Assessment |
| ||
| Mild ptosis (OD) | Eye disorders | Systematic Assessment |
| ||
| Nausea | General disorders | Systematic Assessment |
| ||
| Obscured vision in study eye | Eye disorders | Systematic Assessment |
| ||
| Ocular pain | Eye disorders | Systematic Assessment |
| ||
| Ocular ache/pain in outer corner of non-study eye | Eye disorders | Systematic Assessment |
| ||
| Ocular pain the night of the surgery | Eye disorders | Systematic Assessment |
| ||
| Ocular redness | Eye disorders | Systematic Assessment |
| ||
| Patient was hospitalized for urinary track infection | General disorders | Systematic Assessment |
| ||
| Patient went to ER for bronchitis | Eye disorders | Systematic Assessment |
| ||
| Photophobia | Eye disorders | Systematic Assessment |
| ||
| Post-operative ocular pain | Eye disorders | Systematic Assessment |
| ||
| Post-operative mild graft edema | Eye disorders | Systematic Assessment |
| ||
| Post-operative AC cells | Eye disorders | Systematic Assessment |
| ||
| Post-operative stromal edema | Eye disorders | Systematic Assessment |
| ||
| Post-operative mild irritation and soreness | Eye disorders | Systematic Assessment |
| ||
| Post-operative high intraocular pressure | Eye disorders | Systematic Assessment |
| ||
| Post-operative aching/burning in study eye | Eye disorders | Systematic Assessment |
| ||
| Post-operative epithelial defect | Eye disorders | Systematic Assessment |
| ||
| Post-operative tearing | Eye disorders | Systematic Assessment |
| ||
| Post-operative edema (3+) | Eye disorders | Systematic Assessment |
| ||
| Post-operative wound leak at clock hour 4 | Eye disorders | Systematic Assessment |
| ||
| Post-operative acid reflux | Eye disorders | Systematic Assessment |
| ||
| Post-operative diffuse graft edema | Eye disorders | Systematic Assessment |
| ||
| Post-operative increase in mucus in study eye | Eye disorders | Systematic Assessment |
| ||
| Post-operative light sensitivity (OU) | Eye disorders | Systematic Assessment |
| ||
| Post-operative low Intaocular Pressure | Eye disorders | Systematic Assessment |
| ||
| Post-operative iritis (OS) | Eye disorders | Systematic Assessment |
| ||
| Posterior Capsular Opacity (OS) | Eye disorders | Systematic Assessment |
| ||
| Possible rejection | Eye disorders | Systematic Assessment |
| ||
| Punctate epithelial erosions (OS) | Eye disorders | Systematic Assessment |
| ||
| Retinal tear | Eye disorders | Systematic Assessment |
| ||
| Ring of pink around the eye | Eye disorders | Systematic Assessment |
| ||
| Retinal tear following a clinical laser procedure | Eye disorders | Systematic Assessment |
| ||
| Retained lens cortex inferior (OS) | Eye disorders | Systematic Assessment |
| ||
| Recurrent herpes keratitis | General disorders | Systematic Assessment |
| ||
| Severe ocular pain | Eye disorders | Systematic Assessment |
| ||
| Stromal edema | Eye disorders | Systematic Assessment |
| ||
| Stinging upon instillation | Eye disorders | Systematic Assessment |
| ||
| Shortness of breath and swelling in leg | Eye disorders | Systematic Assessment |
| ||
| bruised eye | Eye disorders | Systematic Assessment |
| ||
| increase in back pain | Eye disorders | Systematic Assessment |
| ||
| scraped leg which became infected and resulted in debridement on July 20th. | Eye disorders | Systematic Assessment |
| ||
| graft failure | Eye disorders | Systematic Assessment |
| ||
| eye feeling heavier/tighter than usual | Eye disorders | Systematic Assessment |
| ||
| fever/flu with redness in eye | Eye disorders | Systematic Assessment |
| ||
| new scrape on leg | General disorders | Systematic Assessment |
| ||
| Subject visited podiatrist as toenail was falling off | General disorders | Systematic Assessment |
| ||
| fungal infection in the OD | Eye disorders | Systematic Assessment |
| ||
| "ping or a pluck" sensation | Eye disorders | Systematic Assessment |
| ||
| vision decreased | Eye disorders | Systematic Assessment |
| ||
| flashes of light | Eye disorders | Systematic Assessment |
| ||
| pain behind non-study eye | Eye disorders | Systematic Assessment |
| ||
| blood in stool | Eye disorders | Systematic Assessment |
| ||
| black strips in vision non-study eye | Eye disorders | Systematic Assessment |
| ||
| increase in leg cramps | General disorders | Systematic Assessment |
| ||
| urinary tract infection | General disorders | Systematic Assessment |
| ||
| seasonal allergies | Eye disorders | Systematic Assessment |
| ||
| hand surgery on his right hand | Eye disorders | Systematic Assessment |
| ||
| open blister on leg, which subject attributes to the CHF | Eye disorders | Systematic Assessment |
| ||
| Sub-epithelial infiltrates | Eye disorders | Systematic Assessment |
| ||
| vertigo, light-headedness, and slight nausea | Eye disorders | Systematic Assessment |
| ||
| headache | General disorders | Systematic Assessment |
| ||
| seeing rust colors when looking at lights | Eye disorders | Systematic Assessment |
| ||
| left pupil appears to be smaller than right | Eye disorders | Systematic Assessment |
| ||
| Superior neurocystic edema (OD) | Eye disorders | Systematic Assessment |
| ||
| Tearing | Eye disorders | Systematic Assessment |
| ||
| Tenderness (OS) | Eye disorders | Systematic Assessment |
| ||
| Trichiatic lashes | Eye disorders | Systematic Assessment |
| ||
| Visual disturbances following a clinical laser procedure | Eye disorders | Systematic Assessment |
| ||
| Wound leak | Eye disorders | Systematic Assessment |
| ||
| Vitreous Hemorrhage | Eye disorders | Systematic Assessment |
| ||
| Ocular discomfort | Eye disorders | Systematic Assessment |
| ||
| Ocular burning upon instilling ophthalmic medication (Pred Forte and Vigamox) | Eye disorders | Systematic Assessment |
| ||
| Ocular burning upon using eye drops in study eye | Eye disorders | Systematic Assessment |
| ||
| Ocular discomfort (OD) | Eye disorders | Systematic Assessment |
| ||
| Ocular hypertension | Eye disorders | Systematic Assessment |
| ||
| Ocular discomfort when closing eyelids tightly (OS) | Eye disorders | Systematic Assessment |
| ||
| Ocular eye irritation (OD) | Eye disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Reza Dana, M.D., M. Sc, MPH | Mass. Eye and Ear | 6175734331 | Reza_Dana@meei.harvard.edu |
| Apr 29, 2020 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D016510 | Corneal Neovascularization |
| ID | Term |
|---|---|
| D003316 | Corneal Diseases |
| D005128 | Eye Diseases |
| D009389 | Neovascularization, Pathologic |
| D008679 | Metaplasia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| D002266 | Carboxymethylcellulose Sodium |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D008747 | Methylcellulose |
| D002482 | Cellulose |
| D005936 | Glucans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided
| >=65 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|
|